Skip to content

Research at St Andrews

Perspective for precision medicine for tuberculosis

Research output: Contribution to journalReview article

Author(s)

Christoph Lange, Rob Aarnoutse, Dumitru Chesov, Reinout van Crevel, Stephen H. Gillespie, Hans-Peter Grobbel, Barbara Kalsdorf, Irina Kontsevaya, Arjan van Laarhoven, Tomoki Nishiguchi, Anna Mandalakas, Matthias Merker, Stefan Niemann, Niklas Köhler, Jan Heyckendorf, Maja Reimann, Morten Ruhwald, Patricia Sanchez-Carballo, Dominik Schwudke, Franziska Waldow & 1 more Andrew R. DiNardo

School/Research organisations

Abstract

Tuberculosis is a bacterial infectious disease that is mainly transmitted from human to human via infectious aerosols. Currently, tuberculosis is the leading cause of death by an infectious disease world-wide. In the past decade, the number of patients affected by tuberculosis has increased by ~20 percent and the emergence of drug-resistant strains of Mycobacterium tuberculosis challenges the goal of elimination of tuberculosis in the near future. For the last 50 years, management of patients with tuberculosis has followed a standardized management approach. This standardization neglects the variation in human susceptibility to infection, immune response, the pharmacokinetics of drugs, and the individual duration of treatment needed to achieve relapse-free cure. Here we propose a package of precision medicine-guided therapies that has the prospect to drive clinical management decisions, based on both host immunity and M. tuberculosis strains genetics. Recently, important scientific discoveries and technological advances have been achieved that provide a perspective for individualized rather than standardized management of patients with tuberculosis. For the individual selection of best medicines and host-directed therapies, personalized drug dosing, and treatment durations, physicians treating patients with tuberculosis will be able to rely on these advances in systems biology and to apply them at the bedside.
Close

Details

Original languageEnglish
Article number566608
Number of pages9
JournalFrontiers in Immunology
Volume11
DOIs
Publication statusPublished - 8 Oct 2020

    Research areas

  • Precision medicine, Tuberculosis, Tailor-made regimen, Mycobacterial genotypes, Endotypes

Discover related content
Find related publications, people, projects and more using interactive charts.

View graph of relations

Related by author

  1. Modelling the effects of environmental heterogeneity within the lung on the tuberculosis life-cycle

    Pitcher, M. J., Bowness, R., Dobson, S. A., Eftimie, R. & Gillespie, S. H., 6 Aug 2020, In : Journal of Theoretical Biology. 506, 18 p., 110381.

    Research output: Contribution to journalArticle

  2. Culture-free proof of Mycobacterium tuberculosis - a new assay for viable bacteria

    Heyckendorf, J., Gillespie, S. H. & Ruhwald, M., Dec 2020, In : EBioMedicine. 62, 2 p., 103117.

    Research output: Contribution to journalComment/debate

  3. Tuberculosis bacillary load, an early marker of disease severity and treatment response: the utility of tuberculosis Molecular Bacterial Load Assay

    Sabiiti, W., Azam, K., Farmer, E., Kuchaka, D., Mtafya, B., Bowness, R., Oravcova, K., Honeyborne, I., Evangelopoulos, D., McHugh, T. D., Khosa, C., Rachow, A., Heinrich, N., Kampira, E., Davies, G., Bhatt, N., Ntinginya, E. N., Viegas, S., Jani, I., Kamdolozi, M. & 8 others, Mdolo, A., Khonga, M., Boeree, M. J., Phillips, P. PJ., Sloan, D. J., Hoelscher, M., Kibiki, G. & Gillespie, S. H., Jul 2020, In : Thorax. 75, 7, p. 606-608 3 p.

    Research output: Contribution to journalArticle

Related by journal

  1. Frontiers in Immunology (Journal)

    Val Smith (Member of editorial board)

    20172018

    Activity: Publication peer-review and editorial work typesPeer review of manuscripts

Related by journal

  1. Atherosclerosis linked to aberrant amino acid metabolism and immunosuppressive amino acid catabolizing enzymes

    Zaric, B. L., Radovanovic, J. N., Gluvic, Z., Stewart, A. J., Essak, M., Motwalli, O., Gojobori, T. & Isenovic, E. R., 28 Sep 2020, In : Frontiers in Immunology. 11, 27 p., 551758.

    Research output: Contribution to journalReview article

  2. Does natural killer cell deficiency (NKD) increase the risk of cancer? NKD may increase the risk of some virus induced cancer

    Moon, W. Y. & Powis, S. J., 19 Jul 2019, In : Frontiers in Immunology. 10, 5 p., 1703.

    Research output: Contribution to journalReview article

  3. Phenotypic changes on Mycobacterium tuberculosis-specific CD4 T cells as surrogate markers for tuberculosis treatment efficacy

    Ahmed, M. I. M., Ntinginya, N. E., Kibiki, G., Mtafya, B. A., Semvua, H., Mpagama, S., Mtabho, C., Saathoff, E., Held, K., Loose, R., Kroidl, I., Chachage, M., Both, U. V., Haule, A., Mekota, A-M., Boeree, M. J., Gillespie, S. H., Hoelscher, M., Heinrich, N., Geldmacher, C. & 1 others, Pan African Consortium for the Evaluation of Antituberculosis Antibiotics (PanACEA), 28 Sep 2018, In : Frontiers in Immunology. 9, 13 p., 2247.

    Research output: Contribution to journalArticle

ID: 270639831

Top